EANS-News: Sangui Bio Tech International Inc. / Granulox has positive influence on healing of leg ulcers

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development/Clinical study

Witten, German, December 12, 2012 (euro adhoc) - Most extensive
clinical study so far at Karls University in Prague shows Granulox
has positive influence on healing of leg ulcers Results to be
published in issue 3/2013 of renowned medical journal

Witten, Germany, December 12, 2012 A report on the course and results
of a comparative clinical study carried out under the direction of
professor Petr Arenberger, MD, at the clinic of dermatology at the
Karls University in Prague was now accepted for publication. The
study aimed to investigate into the influence of a hemoglobin based
spray on the healing progress of leg ulcer. Leg ulcer is one the most
prolific origins of chronic wounds with a prevalence of about 1.5
million cases p. a. in Germany alone. This was the most extensive
clinical study regarding this technology to support wound healing as
developed by Sangui. The prospective, randomized and placebo
controlled study gave highly significant evidence that there is a
clearly positive influence of the hemoglobin spray on wound healing.
The eminent efficacy of Granulox (e. g. in patients suffering from
leg ulcer) is now documented one more time on the highest scientific
level. The entire study including all findings, in particular
regarding the improvement of healing times and the reduction of pain
experienced by the patients will be published in the 3/2013 issue of
"Der Hautarzt" (Springer Verlag (Heidelberg)). "Der Hautarzt" enjoys
international acceptance and is amply quoted. The journal informs
clinical and practising dermatologists on a regular basis of all
important developments in all areas of dermatology. Articles are not
published unless they have passed a peer review.

Further inquiry note:
Dr. Joachim Fleing
Fon: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Sangui Bio Tech International Inc.
Alfred-Herrhausen-Strasse 44
D-58455 Witten
phone: +49(0)2302 915-200
FAX: +49(0)2302 915-191
mail: info@sangui.de
WWW: http://www.sanguibiotech.com
sector: Biotechnology
ISIN: DE0000906757
indexes:
stockmarkets: free trade: Hamburg, New York
language: English